Therapeutic nuclear medicine therapy for metastatic castrate resistant prostate cancer

This page provides information about new therapeutic nuclear medicine therapy Medicare services for patients with advanced prostate cancer, where prior treatment has failed.

Page last updated: 13 June 2025

From 1 July 2025, two new items for 177Lutetium (Lutetium) prostate specific membrane antigen (PSMA) therapy (16050 and 16055) will be listed on the Medicare Benefits Schedule for the treatment of patients with progressive or symptomatic metastatic castrate-resistant prostate cancer, where prior treatment has failed.

A new whole-body PSMA positron emission tomography diagnostic imaging item (61528) will also be listed to determine a patient’s suitability to undergo Lutetium PSMA therapy.

Further information is provided in the Factsheet below:

PDF Version - Therapeutic nuclear medicine therapy for metastatic castrate resistant prostate cancer.pdfPDF Version - Therapeutic nuclear medicine therapy for metastatic castrate resistant prostate cancer.pdf

Word Version - Therapeutic nuclear medicine therapy for metastatic castrate resistant prostate cancer.docxWord Version - Therapeutic nuclear medicine therapy for metastatic castrate resistant prostate cancer.docx

In this section